Zydus Lifesciences Ltd

Zyudus Lifesciences Limited announced that shareholders at its Thirty First Annual General Meeting on August 11, 2026, approved the re-appointment of Dr. Sharvil P. Patel as Managing Director for a five-year period effective April 1, 2027, to March 31, 2032, and the appointment of Mr. Kulin S. Lalbhai as an Independent Director for a five-year term effective May 19, 2026, to May 18, 2031.

Zydus Lifesciences Ltd share price gained 0.49% to Rs 1120.7 after the company's net profit tanked by 28.99% to Rs 952.4 crore, while revenue from operations slightly gained 4.94% to Rs 7802.0 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.56 lakh crore, gaining 4.63%. It has marginally improved by 0.56% over last one week and climbed by 13.27% in last one month while the market capitalization of Zydus Lifesciences Ltd has inched up 0.20% and 18.32% in the same period respectively. Profit before tax (PBT) of Zydus Lifesciences Ltd stood at Rs 1306.6 crore in Q2 FY26, plunging by 31.97% year-on-year, and tumbling by 21.27% quarter-on-quarter. EBITDA came in at Rs 1823 crore, slipping 5.70% YoY and nosediving by 24.66% sequentially. Total expenses rose by 19.88% to Rs 6642.3 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 1251.2 crore, marginally falling by 7.13% YoY, while employee benefits expense was at Rs 1368.2 crore, rising by 10.45% YoY. For the TTM ended FY26, revenue from operations grew 18.37% to Rs 26719.7 crore, while net profit grew slightly 8.92% to Rs 5026.4 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 728020% to Rs 7965.6 crore, and PBT saw a minor gain of 9.86% to Rs 6621.1 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 2116.6 crore in FY26, as against Rs 6781.1 crore in FY25. Zydus Lifesciences Ltd surged by 17.29% in last one year, significantly outperforming the benchmark BSE Sensex which has eased by 2.56% during the same period.

Zydus Lifesciences Ltd gained for a third straight session today. The stock is quoting at Rs 1159, up 3.57% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.51% on the day, quoting at 24458.4. The Sensex is at 78138.33, down 0.51%. Zydus Lifesciences Ltd has risen around 2.45% in last one month. Meanwhile, Nifty Pharma index of which Zydus Lifesciences Ltd is a constituent, has risen around 3.63% in last one month and is currently quoting at 26479.55, up 0.36% on the day. The volume in the stock stood at 17.56 lakh shares today, compared to the daily average of 10.25 lakh shares in last one month. The benchmark August futures contract for the stock is quoting at Rs 1162.1, up 3.88% on the day. Zydus Lifesciences Ltd is up 21.28% in last one year as compared to a 0.12% drop in NIFTY and a 22.17% drop in the Nifty Pharma index.The PE of the stock is 30.29 based on TTM earnings ending March 26.

Zydus Lifesciences Limited announced it has received final approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Indocyanine Green for Injection, a generic equivalent of Diagnostic Green LLC’s IC-Green®, and is eligible for 180-days of CGT exclusivity. The product, which will be manufactured at a USFDA-approved facility in Gujarat and marketed in the U.S. by Zydus Pharmaceuticals (USA) Inc., is indicated for fluorescence imaging and had annual sales of approximately USD 125.8 million in the United States as of June 2026.

Zydus Lifesciences Limited announced on August 1, 2026, that it has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its injectable facility at Zydus Biotech Park in Ahmedabad, India, with a Voluntary Action Indicated (VAI) classification, following a Good Manufacturing Practice (GMP) surveillance inspection conducted from April 27 to May 5, 2026.

Zydus Lifesciences Ltd dropped for a fifth straight session today. The stock is quoting at Rs 1106.7, down 0.18% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 0.86% on the day, quoting at 23972.3. The Sensex is at 76761.63, up 0.92%.Zydus Lifesciences Ltd has lost around 1.3% in last one month.Meanwhile, Nifty Pharma index of which Zydus Lifesciences Ltd is a constituent, has increased around 2.83% in last one month and is currently quoting at 25548.15, up 1.54% on the day. The volume in the stock stood at 3.8 lakh shares today, compared to the daily average of 13.4 lakh shares in last one month. The benchmark July futures contract for the stock is quoting at Rs 1108.1, down 0.12% on the day. Zydus Lifesciences Ltd jumped 12.92% in last one year as compared to a 2.87% slide in NIFTY and a 13.98% spurt in the Nifty Pharma index.The PE of the stock is 29.97 based on TTM earnings ending March 26.Powered by Capital Market - Live

Zydus Lifesciences has received permission to conduct a Phase III clinical trial of Desidustat for patients with sickle cell disease. Conducted in collaboration with the Indian Council of Medical Research (ICMR), the 203-day study will evaluate the efficacy and safety of Desidustat oral tablets in treating anemia. The trial will enrol 164 patients diagnosed with the disease. Sickle Cell Disease is a significant public health concern in India, especially among tribal populations where prevalence is higher. According to National Health Mission estimates, nearly 20 million people live with the condition, and roughly 50,000 children are born with sickle cell anaemia annually. While treatments like hydroxyurea and blood transfusions exist, their limited accessibility, inconsistent effectiveness, and associated risks remain significant challenges.

Zydus Lifesciences will hold a meeting of the Board of Directors of the Company on 11 August 2026.

Zydus Lifesciences and Guardant Health, Inc., a leading precision oncology company, have an exclusive agreement to make the Shield' Multi-Cancer Detection (MCD) test available in India, for which Zydus has signed a Memorandum of Understanding (MoU) with Apollo Hospitals to offer the test in the territory. The Shield MCD test is a methylation-based blood test for the detection of multiple cancer types including bladder, colorectal, breast, prostate, oesophageal, gastric, liver, lung, ovarian and pancreas cancer in individuals aged 45 or older and who are at typical average risk for cancer. With just a blood draw, the test screens for 10 of the most common cancers, many of which have high mortality rates in India. The test has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA), recognising its potential to provide more effective screening for cancers than existing options.

Shares of Apollo Hospitals Enterprise also gained 1.73% to Rs 8,848 on the BSE. Under an exclusive agreement with Zydus Lifesciences, Guardant Health will commercialise the Shield MCD test in India, while Apollo Hospitals will offer the test through its healthcare network. The Shield MCD test is a methylation-based blood test for the detection of multiple cancer types including bladder, colorectal, breast, prostate, oesophageal, gastric, liver, lung, ovarian and pancreas cancer in individuals aged 45 or older and who are at typical average risk for cancer. The test has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA), recognising its potential to provide more effective screening for cancers than existing options. Speaking on this development, Dr. Prathap C. Reddy, chairman, Apollo Hospitals Group, said, At Apollo, we have long believed that the most effective healthcare is proactive healthcare. The future of medicine lies not only in treating disease, but in preventing it and detecting it at its earliest, most treatable stages. Cancer continues to be one of the greatest health challenges facing societies worldwide, and expanding access to timely, reliable screening, is critical to reducing its impact. Our collaboration with Zydus Lifesciences marks an important milestone in advancing accessible, patient-friendly cancer screening solutions for the people of India.' Dr. Sharvil Patel, managing director, Zydus Lifesciences, said, 'As India's leading oncology company, we are reimagining the role of diagnostics in cancer care. We are pleased to partner with Apollo Hospitals and Guardant Health to introduce Shield MCD in India, expanding access to an innovative screening technology that complements existing screening pathways.' Simranjit Singh, chief executive officer, Guardant Health AMEA added, We are pleased to bring the Shield Multi-Cancer Detection (MCD) test to India through Apollo Cancer Centres and our longstanding commercial partner Zydus Lifesciences. Earlier detection has the potential to transform cancer outcomes, and Shield MCD represents an important advancement in helping identify cancer-associated signals through a single blood draw.' Zydus Lifesciences is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. Apollo Hospitals was established in 1983 by Dr. Prathap C Reddy, renowned architect of modern healthcare in India. It has a robust presence across the healthcare ecosystem, including Hospitals, Pharmacies, Primary Care & Diagnostic Clinics and several Retail Health models. Powered by Capital Market - Live